Melting points of the synthesized compounds were determined in capillaries. 1 H and 13 C NMR spectra were recorded on Bruker Advance 400 MHz spectrometers using CDCl 3 as solvent.
(E)-3-(3-(4-Methoxyphenyl)acryloyl)-2H-chromen-2-one (6a)
Light brown, R f = 0.44, Yield: 92 %. 1 
(E)-3-(3-(3,4,5-Trimethoxyphenyl)acryloyl)-2H-chromen-2-one (6b)
Pale Yellow, R f = 0.41, Yield: 94 %. 1 
(E)-3-(3-(4-Chlorophenyl)acryloyl)-2H-chromen-2-one (6c)
Brown, R f = 0.46, Yield: 70 %. 1 
(E)-3-(3-(4-Nitrophenyl)acryloyl)-2H-chromen-2-one (6d)
Brown, R f = 0. 
3-Cinnamoyl-2H-chromen-2-one (6e)
Light orange, R f = 0.45, Yield: 65 %. 1 
(E)-3-(3-(4-Hydroxyphenyl)acryloyl)-2H-chromen-2-one (6f)
Dark brown, R f = 0.43, Yield: 75%. 
(E)-3-(3-(2-Methoxyphenyl)acryloyl)-2H-chromen-2-one (6g)
Brown, R f = 0.42, Yield: 69 %. 
General method for the preparation of Coumarin based Pyrazolines (7)
In a round bottom flask, a solution of coumarin chalcones (6, 0.5g) and hydrazine hydrate (1eq) in glacial acetic acid (5ml) was added and refluxed at 80 o C for 8 h. The progression of reaction was observed by TLC. After completion of reaction, mixture was poured into the crushed ice with continuous stirring and kept aside for 15-20 minutes. The precipitates obtained was filtered and washed with water. The crude product was purified by column chromatography with 10-15% EtOAc in hexane to afford the desired product (7a-g).
3-(1-Acetyl-5-(4-methoxyphenyl)-4, 5-dihydro-1H-pyrazol-3-yl)-2H-chromen-2-one (7a)
Light 
3-(1-Acetyl-5-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl)-2H-chromen-2-one (7b)
Brown 
3-(1-Acetyl-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl)-2H-chromen-2-one (7c)
3-(1-Acetyl-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazol-3-yl)-2H-chromen-2-one (7d)
Light brown, R f = 0. 
3-(1-Acetyl-5-phenyl-4,5-dihydro-1H-pyrazol-3-yl)-2H-chromen-2-one (7e)
3-(1-Acetyl-5-(4-hydroxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl)-2H-chromen-2-one (7f)
Brown, R f = 0.45, 
3-(1-Acetyl-5-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl)-2H-chromen-2-one (7g)
Brown, R f = 0.37, Mp 150- 
Biological evaluation

In-vitro anti-inflammatory activity
In-vitro COX inhibition assay: The effect of synthesized compounds (7a-g) on COX-1 and COX-2 were evaluated using COX (ovine) inhibitor screening assay EIA kit (Catalogue No. 560101, Cayman Chemicals Inc., Ann Arbor, MI, USA) according to manufacturer's instructions. The compounds were dissolved in dimethylsulfoxide (DMSO). The enzyme COX-1 and COX-2 (10 μL), heme (10 μL) and compounds (20 μL) were added to the supplied reaction buffer solution (950 μL, 0.1 M Tris-HCl, pH 8 containing 5 mM ethylenediaminetetraacetate and 2 mM phenol). The mixture of these solutions was incubated for a period of 10 min at 37 º C, and then COX reactions were initiated by adding arachidonic acid (10 μL, making final concentration 100 μM) solution. The COX reactions were quenched by addition of HCl (1 M, 50 μL) after 2 min and then saturated stannous chloride (100 μL) was added and again incubated for 5 min at room temperature. The PGF 2α formed by COX reactions was quantified by EIA. The pre-coated 96-well plate containing compounds was incubated for 18 h at room temperature. After incubation, the plate was washed to remove any unbound reagent and then Ellman's reagent (200 μL), was added followed by incubation for 60 min (until the absorbance of B o well is in the range 0.3-1.0 A. U.) at room temperature. The plate was then read by an ELISA plate reader at 410 nm.
Inhibition of albumin denaturation:
The anti-inflammatory activity of synthesized compounds 7a-g was determined by using the procedure for inhibition of albumin protein denaturation as previously reported. 2
Membrane stabilization: Membrane stabilization assays such as Heat-induced hemolysis and
Hypotonicity-induced hemolysis was performed by following the already reported method. 2
In-vivo anti-inflammatory and analgesic activity:
The analgesic and anti-inflammatory activity of the compounds were performed by using male Wistar rat (4-6 weeks old), weighing 150-200 g procured from Central Animal House facility of ISF College of Pharmacy, Moga, Punjab India. They were housed in polypropylene cages with four of them in one cage and maintained at a temperature range of 22-24˚C with access to standard animal food and clean drinking water. Our animal house and breeding facility is registered with the Committee for the
Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Government of
India and CPCSEA guidelines were followed (CPCSEA approval number ISFCP/IAEC/CPCSEA/2017/354). The analgesic and anti-inflammatory activity of the compounds were carried out using our previously reported procedure. 3, 4 Estimation of Cytokine levels: The cytokines level were estimated in vivo by using rat TNF-α, IL-6, and IL-1β immunoassay kit (KRISHGEN Biosystem, Ashley Ct, Whittier, CA). 4 Acute toxicity studies: Acute toxicity studies were performed with synthesized compounds on either sex rats according to OECD guidelines. 3, 4 Animals were fasted for 4h prior to dosing and for further 2h after dosing. The first group was treated as control and the second group was treated with synthesized compound at a dose of 50 mg/kg. The third group was treated with synthesized compound at a dose of 300 mg/kg, and the fourth group was treated with synthesized compound at a dose of 2000 mg/kg. All treatments were given orally in a single dose. First 4h the animals were observed continuously followed by periodic monitoring for 24h. Thereafter, the animals were observed once or twice daily for a period of 14 days.
Molecular docking study:
The molecular docking studies on the synthesized compounds were carried out by molecular docking software gold version 5.0 for predicting the binding affinity of synthesized compounds with COX-2, COX-1 and 5-LOX. The X-ray crystallographic structure of the selected proteins COX-2 (PDB 3LN1), COX-1 (PDB 3KK6) and 5-LOX (PDB 3V99) were procured from protein data bank. [5] [6] [7] [8] The protein and ligand preparation were carried out using MOE (molecular Operating Environment). All the synthesized compounds were energy minimized by selecting force field MMFF94X with gradient value of 0.0001 Kcal/mol. The energy minimized compounds were docked in the active site of the target protein. Docking protocol was validated by redocking of co-crystallized structure and RMSD value was calculated. Table S1 : Effect of coumarin-pyrazolines 7a-g on albumin denaturation. Etoricoxib 10 0.198±0.003*** 71 Each value represents the mean ± SD. n=3, A significant difference between the test and standard group were considered when test group = *(p<0.05), **(p<0.01), *** (p<0.001) using Bonferroni test by applying two-way ANOVA. Etoricoxib 10 0.217±0.007*** 52 Each value represents the mean ± SD. n=3, A significant difference between the test and standard group were considered when test group = *(p<0.05), **(p<0.01), ***(p<0.001) using Bonferroni test by applying two-way ANOVA. Logarithm of compound partition coefficient between n-octanol and water; i Logarithm of water solubility.
5-LOX Inhibition by Compound 7a:
The procedure for screening of compound 7a against 5-LOX inhibition was used as described in literature. 9 
